Epione Advises: 100th Patient Milestone with Epione® Achieved at US Hospital

This week, Epione will celebrate another milestone at a leading cancer institute where the 100th patient will be treated using the technology. Epione, a robotic- assisted platform used in interventional oncology, is designed to support physicians during minimally invasive, percutaneous ablations of abdominal tumors.

“Many patients cannot undergo extensive surgery, or their tumors are considered inoperable for various reasons, and image-guided ablation is a minimally invasive treatment option for them,” shared Dr. Govindarajan Narayanan, Chief of Interventional Oncology with Miami Cancer Institute and Miami Cardiac & Vascular Institute, part of Baptist Health South Florida.

He added, “Robotic- assisted ablations allow physicians to plan and place the ablation probe with precision and obtain post-procedure confirmation of ablation success while reducing the radiation exposure to the patient and the physician.”

A minimally invasive procedure, Epione uses CT-guided navigation for the percutaneous ablation of tumors in the abdomen. A robotic arm guides physicians to the best entry point, allowing them to precisely insert a needle while avoiding critical structures. Because physicians can quickly perform these procedures, patients may be able to go home the same day.

“Our mission has been to develop state-of-the-art technology that has the potential to help physicians improve the lives of patients diagnosed with cancer,” said Bertin Nahum, CEO and co- founder of Quantum Surgical. “With yet another significant milestone, Epione has proved its relevance for interventional oncology. We aim to expand the availability of less invasive treatments for a greater number of patients.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”